HXN-2001 / Earendil Labs - LARVOL DELTA

Design and development of a biparatopic antibody-drug conjugate against CDH17 (AACR 2026) - "The ADCs showed selective cytotoxicity towards multiple tumor cell lines with varying levels of CDH17 expression in vitro, and potently inhibited the growth of CDH17-expressing tumor xenografts in animal models. Together, these findings indicate that our lead biparatopic anti-CDH17 ADC is a promising candidate for the treatment of cancers that overexpress CDH17."

ADC • IO biomarker • Oncology • Pancreatic Cancer • Solid Tumor • CDH17